Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 15/20 | 0.53 |
| ▸ | CA2 | P00918 | 15/20 | 0.53 |
| ▸ | CA9 | Q16790 | 15/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4408548 | 0.91 | MAPT (0.43) | CA1CA2CA9PTGS2PTGS1 | |
| SCHEMBL5115054 | 0.87 | CA2 (0.53) | CA1CA2CA9PTGS2PTGS1 | |
| SCHEMBL5114812 | 0.87 | CA2 (0.53) | CA1CA2CA9PTGS2PTGS1 | |
| SCHEMBL4407942 | 0.81 | PTGS2 (0.47) | CA1CA2CA9PTGS2PTGS1 | |
| SCHEMBL5108985 | 0.81 | CA1 (0.58) | CA1CA2CA9PTGS2CA12 | |
| SCHEMBL3760769 | 0.78 | NOS1 (0.47) | CA1CA2CA9CA12CDK2 | |
| SCHEMBL5123349 | 0.78 | PTGS2 (0.55) | CA1CA2CA9PTGS2PTGS1 | |
| SCHEMBL3333982 | 0.78 | CA1 (0.54) | CA1CA2CA9PTGS2PTGS1 | |
| SCHEMBL4411190 | 0.78 | NOS1 (0.54) | CA1CA2CA9PTGS2PTGS1 | |
| SCHEMBL4415363 | 0.78 | KCNH3 (0.39) | CA1CA2CA9PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318456-A1 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318456-A1 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318456-A1 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2008003149-A2 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES , INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318456-A1 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | HAVCR2, TYMP, HCCS | CA1 4865/4885CA2 4750/4885CA9 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.